SECTOR:
HEALTHTECH (B2B)
HEADQUARTERS:
CAMBRIDGE, USA
IVYCAP INVESTMENT:
2020

Abhishek, Swetabh and Richard transform drug discovery using machine learning!

The exponential growth of biomedical molecular data has reduced its usability, eventually slowing down the drug discovery process, making it more expensive. Elucidata’s proprietary SaaS platform - Polly, uses machine learning (ML) to accelerate the drug discovery process. The platform hosts a rich archive of over 230,000 multi-omic datasets, curated semi-automatically, with over 50,000 new datasets added each month.

Today, Elucidata has 35+ research partners from premier biopharma companies and research labs across the globe using Polly and supports the discovery programs at Pfizer, Agios Pharmaceuticals, Genentech and Yale.

leaf
The relationship between IvyCap and the brand
IvyCap and Ashish have been phenomenal partners in our growth journey. It has been over a year since my first call with Vikram, and every subsequent interaction with IvyCap has deepened our relationship. As a first time founder, I have found their contributions to go far beyond their capital investment. I am thrilled to have them on our side as we continue to establish Elucidata as a market leader. We greatly value the partnership we share with Ivy Cap and look forward to the journey ahead.
- Dr Abhishek Jha,
Co-Founder & CEO
We have been associated with Ivy Cap since December last year. My team and I have worked closely with Ashish Wadhwani. His advice has been invaluable to us on countless occasions. He has guided us with his expertise and domain knowledge to face many challenges which an early age startup faces. He is a great venture capitalist and a committed member of the team who supports in navigating through critical challenges with ease. Ivy Cap has helped us with reaching out to domain experts for various needs and has been very accessible. Their market knowledge, business acumen and network have ensured the organization’s optimum growth. Special shout to the team when they extended the hand of support during the Covid -19 pandemic. We are grateful for their ongoing support.
- Swetabh Pathak,
Co-Founder & CTO
FOUNDERS
Dr Abhishek Jha
Co-Founder & CEO
Before starting Elucidata, Abhishek was an early member of the platform team at Agios Pharmaceuticals and helped bring 2 first in class drugs for acute myeloid leukemia to FDA approval. He was previously trained at MIT, The University of Chicago and IIT Bombay.
Swetabh Pathak
Co-Founder & CTO
Prior to co-founding Elucidata, he has been a founding member and Product Manager at start-ups in technology and affordable STEM education and has an integrated Masters in Mathematics and Computer Science from IIT Delhi.
Their
Winning
Edge

01

Data & Technology
Our proprietary ML-based curation infrastructure powers data curation at scale, allowing us to equip scientists with harmonized, ML-Ready biomolecular data at a high velocity

02

Processes
Our Robust curation processes include in-depth curation and review guidelines ensuring high accuracy of curation labels, that form the basis for our superior ML models

03

Solutions
Our multi-disciplinary team of bio-informaticians, biologists, data scientists, and engineers help develop customized solutions for modern-day R&D teams to fast track their journey from data generation to insight discovery
Elucidata IN COVERS